Geron Corporation (GERN NASDAQ) stock market data APIs
$1.6148
-0.1(-6.2%)
as of March 9, 2026
Try our APIs with
free plan!
Geron Corporation Financial Data Overview
Price chart is built with
Anychart
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Prev. Close
1.6148
Open
1.5145
High
1.634
Low
1.5059
52 wk Range
1.04-2.01
Market Cap
977 M
Shares Outstanding
638 M
Revenue
184 M
EPS
-0.0212
Beta
0.624
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Geron Corporation (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Geron Corporation data using free add-ons & libraries
Get Geron Corporation Fundamental Data
Geron Corporation Fundamental data includes:
- Net Revenue: 184 M
- EBITDA: -51 079 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-25
- EPS/Forecast: -0.028
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Geron Corporation News
New
Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?
Bristol Myers BMY is banking on its growth portfolio, which comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others, to drive top-line gro...
Geron (GERN) 2025 Revenue Surges to $183.6M Driven by RYTELO Commercial Success
Geron Corporation (NASDAQ:GERN) is one of the most promising penny stocks under $5 to buy. On February 25, Geron Corporation reported earnings results for Q4 and the full year of 2025, fueled by the c...
Geron Corporation Q4 2025 Earnings Call Summary
Geron Corporation Q4 2025 Earnings Call Summary - Moby Strategic Alignment and Commercial Evolution Transitioned from a clinical-stage entity to a commercially minded organization through a strategi...
Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago. These figures are adjusted for non-recu...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
